North America Cancer Biomarkers Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Cancer biomarkers are used to trace and indicate the biological state of a tumour and thus analyse diagnostic and prognostic stages of cancer. Cancer biomarkers are into various fields such as drug discovery, development, personalised medicine, and diagnostics. Diagnostics is the principal revenue-generating application of market relating to factors such as increasing growth of biomarker-based oncology tests with higher sensitivity.

North America Cancer Biomarkers Market Segments Size & growth:

The market is valued at USD 3.996 Billion in 2017 and is expected to reach USD 7.328 Billion by 2024 at a CAGR of 10.11%. The major Key factors influencing the market growth are an increase in awareness among patients and healthcare professionals about the necessity of early diagnostics of malignance’s and rising demand for personalised medicine is anticipated to provide the market with significant growth.

North America Cancer Biomarkers Market Segments Share:

Cancer type segments cancer biomarkers market into breast cancer, lung cancer, colorectal cancer, melanoma; prostate, thyroid etc. over all these breast cancers is holding the most significant share in the market due to the prevalence of breast cancer and awareness about the diagnosis. The cancer biomarkers market is segmented by type, disease, service, application, and technologies. Of the kind, the market is categorised into protein biomarkers, genetic biomarkers, cell biomarkers, viral biomarkers, carbohydrate biomarkers. By disease, the market is classified into prostate cancer, lung cancer, breast cancer, colorectal cancer and cervical cancer. By service, the market is categorised into sample preparation, assay development, biomarkers validation and testing. By application, the market is classified into risk assessment, development of molecular diagnostics, disease diagnostics, drug discovery, and development. By technologies, the market is categorised into Omics technologies, imaging technologies, cytogenetics, bioinformatics and IVD multivariate index assays. Geographically, North America is the dominant region globally, and the United States is the primary contributor. Asia-Pacific is expected to be the fastest growing regional market due to the prevalence of cancer in that region.

North America Cancer Biomarkers Market Trends:

• Abbott got new FDA labelling for some of its MRI active devices and announced the acquisition of st.jude medical, Inc. this transaction provides Abbott with expanded opportunities for future growth.
• Agilent technologies and multiplicon N.V signed an agreement under which Agilent will acquire multiplicon, a leading European diagnostics company.

North America Cancer Biomarkers Market Research Report Includes:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.

To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.

Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year

Identifying DROC in the current market and their impact in altering the market dynamics.

Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.

Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.

The principal market players are:

• Affymetrix Inc
• Illumina Inc
• Abbott Laboratories
• Roche Diagnostics Corp.
• Agilent Technologies